Get started

Financials · BGMS

Bio Green Med Solution Inc. (BGMS) financials

For the twelve months ended Jun 30, 2026, Bio Green Med Solution Inc. reported $1.86M of revenue and -$2.20M of net income.

Revenue, TTM
$1.86M
Net income, TTM
-$2.20M
Net margin
-118.3%
Cash
$3.79M
P/S
2.96
Market cap
$5.5M
Annual revenue$747.0K
FY2016FY2025
Annual net income-$3.00M
FY2016FY2025
Annual free cash flow-$16.12M
FY2016FY2023

BGMS revenue and earnings growth

BGMS revenueQ2 2026$336.0K

QoQ
-56.8%
FY YoY
17x
10Y CAGR
-9.1%

BGMS revenue was $336.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 56.8% from the prior quarter. For the full fiscal 2025 it was $747.0K, up about 17-fold from fiscal 2024. Compound annual growth was -9.1% over 10 years.

BGMS net incomeQ2 2026-$405.0K

BGMS net income was -$405.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.32M a year earlier. For the full fiscal 2025 it was -$3.00M, compared with -$11.21M in fiscal 2024.

BGMS EPSQ2 2026-$0.08

BGMS diluted EPS was -$0.08 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$6.45.

BGMS free cash flowQ2 2026-$352.0K

BGMS free cash flow was -$352.0K in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2023 it was -$16.12M, compared with -$20.83M in fiscal 2022.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$747.0K$43.0K$420.0K$0$0$0-$150.0K$0$843.0K
Research and development$848.0K$6.66M$19.16M$20.27M$14.93M$4.76M$4.66M$4.33M$4.24M$9.48M
Selling, general and admin$7.72M$5.39M$6.72M$7.38M$7.46M$5.88M$5.02M$5.37M$5.25M$5.52M
Operating income-$8.43M-$12.00M-$25.45M-$27.66M-$22.39M-$10.64M-$9.68M-$9.55M-$9.49M-$14.15M
Pre-tax income-$2.99M-$11.99M-$25.55M-$25.91M-$22.18M-$9.68M-$9.13M-$8.63M-$8.46M-$13.77M
Income tax$7.0K-$782.0K-$3.00M-$4.72M-$3.73M-$1.24M-$1.30M-$1.34M-$993.0K-$1.98M
Net income-$3.00M-$11.21M-$22.55M-$21.20M-$18.46M-$8.45M-$7.83M-$7.29M-$7.47M-$11.79M
EPS, basic-$6.45-$502.46-$6419.18-$1.90-$2.09-$3.42-$9.84-$12.40-$39.00-$70.00
EPS, diluted-$6.45-$502.46-$6419.18-$27.24-$2.09-$3.42-$9.84-$12.40-$39.00-$70.00
Diluted shares2.2M22,3143.5M11.3M8.9M3.6M816,080604,706.55381,557.6171,248.8

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$3.50M$3.14M$3.38M$18.34M$36.56M$33.41M$11.88M$17.50M$23.91M$16.52M
Short-term investments---$4.55M$4.48M$5.33M$11.14M$16.69M$22.81M$11.19M
Receivables$1.26M$0$0------$10.0K
Inventory$1.38M---------
Current assets$6.26M$3.67M$7.44M$24.41M$40.94M$35.47M$14.02M$19.79M$25.97M$19.62M
Goodwill$1.57M---------
Total assets$8.19M$4.09M$8.80M$28.05M$43.14M$36.80M$15.31M$19.82M$26.00M$19.66M
Current liabilities$1.33M$6.27M$8.16M$7.51M$5.41M$2.49M$2.42M$4.45M$4.11M$5.26M
Total liabilities$1.34M$6.27M$8.20M$7.62M$5.44M$3.54M$3.61M$4.55M$4.24M$5.39M
Shareholders' equity$6.84M-$2.17M$607.0K$15.94M$37.69M$33.26M$11.70M$15.27M$21.77M$14.27M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$4.77M-$7.99M-$16.11M-$20.83M-$18.54M-$7.93M-$9.45M-$6.70M-$7.48M-$10.08M
Capital expenditures--$6.0K$7.0K$27.0K$96.0K$10.0K$39.0K$13.0K$3.0K
Free cash flow---$16.12M-$20.83M-$18.57M-$8.03M-$9.46M-$6.74M-$7.49M-$10.08M
Investing cash flow---$6.0K-$7.0K-$27.0K-$96.0K$28.0K-$39.0K-$13.0K$9.0K
Financing cash flow$5.26M$7.82M$848.0K$3.00M$21.74M$29.50M$3.85M$429.0K$14.75M$6.59M
Stock-based compensation$2.33M$592.0K$1.47M$1.51M$1.16M$430.0K$466.0K$331.0K$266.0K$782.0K
Depreciation and amortization-----$20.0K$20.0K$29.0K$32.00M$100.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY1637.2%-89.8%-------100.0%-56.6%
Operating margin-1128.1%-27916.3%-6060.2%-----6365.3%--1678.5%
Net margin-401.3%-26074.4%-5370.2%-----4858.7%--1398.7%
Free cash flow margin---3837.6%-----4493.3%--1196.0%
Return on equity-43.8%--3715.8%-133.0%-49.0%-25.4%-66.9%-47.7%-34.3%-82.6%
Return on assets-36.6%-273.9%-256.2%-75.6%-42.8%-22.9%-51.1%-36.8%-28.7%-60.0%
Current ratio4.700.590.913.257.5614.275.794.456.323.73

Source: XBRL data Bio Green Med Solution Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Aug 11, 2016; 1-for-20, first reported May 12, 2020.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BGMS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BGMS$1.86M--$2.20M-118.3%$5.5M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

BGMS FAQ

6 questions
  • What is BGMS revenue?
    Bio Green Med Solution Inc. (BGMS) reported $1.86M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $747.0K.
  • Is BGMS profitable?
    No. Bio Green Med Solution Inc. reported a net loss of $2.20M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does BGMS have?
    Bio Green Med Solution Inc. reported $3.79M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is BGMS revenue growing?
    Bio Green Med Solution Inc.'s revenue changed 17x in fiscal 2025, to $747.0K. Its compound annual growth rate was -9.1% over 10 years.
  • When did BGMS last report financial results?
    The latest statements here come from Bio Green Med Solution Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this BGMS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Bio Green Med Solution Inc. files with the SEC. It is provided for information only and is not investment advice.